Ebos Group (EBO.NZ) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Ebos Group (EBO.NZ) quarterly earnings & revenue
Ebos Group (EBO.NZ) reported revenue of 4.39B NZD for Q2 2026, up 7.4% year-over-year, with net income of 80.96M NZD and diluted EPS of 0.39 NZD.
Over the last four reported quarters, Ebos Group generated 16.17B NZD in revenue and 299.93M NZD in net income.
Ebos Group's next earnings report is scheduled for August 25, 2026; analysts estimate EPS of 0.42 NZD.
Ebos Group quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q2 2026 | 4.39B NZD | +7.4% | 80.96M NZD | 0.39 NZD |
| Q4 2025 | 5.71B NZD | +50.5% | 63.58M NZD | 0.31 NZD |
| Q2 2025 | 1.91B NZD | -51.1% | 70.13M NZD | 0.36 NZD |
| Q4 2024 | 4.16B NZD | +12.7% | 85.26M NZD | 0.42 NZD |
| Q2 2024 | 4.09B NZD | +23.3% | 84.53M NZD | 0.45 NZD |
| Q4 2023 | 3.80B NZD | +22.5% | 75.49M NZD | 0.40 NZD |
| Q2 2023 | 3.91B NZD | +24.6% | 84.14M NZD | 0.44 NZD |
| Q4 2022 | 3.69B NZD | +32.7% | 62.78M NZD | 0.36 NZD |
Ebos Group (EBO.NZ) — frequently asked questions
When does Ebos Group (EBO.NZ) report earnings next?
Ebos Group is expected to report earnings on August 25, 2026. Analysts estimate EPS of 0.42 NZD.
What was EBO.NZ's revenue last quarter?
Ebos Group reported revenue of 4.39B NZD in Q2 2026, up 7.4% from the same quarter a year earlier.
What was EBO.NZ's EPS last quarter?
Ebos Group reported diluted EPS of 0.39 NZD in Q2 2026.
Is Ebos Group profitable?
Ebos Group is currently profitable, with 299.93M NZD in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)